Vaxart (VXRT) Reports First Patient Enrollment in Phase 1b Norovirus Boosting Regimen Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vaxart (VXRT) Says New Data from Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
May 3, 2021 5:07 PM EDTVaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today at Vaxarts key opinion leader event that new data obtained from its Phase I COVID-19 trial added to the evidence suggesting that VXA-CoV2-1, the companys first COVID-19 oral vaccine construct that triggers mucosal immunity and includes both the S and the N SARS-Cov-2 proteins, has broad cross-coronavirus activity.
We have previously announced study data showing that our oral vaccine could be as protective as the... More
Pre-Open Stock Movers 05/03: (MDP) (OCGN) (VIRX) Higher; (VXRT) (PETS) (EL) Lower (more...)
May 3, 2021 9:30 AM EDTToday's Pre-Open Stock Movers
Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) 33% HIGHER; adds to recent momentum gains.
Meredith Corporation (NYSE: MDP) 12.5% HIGHER; today announced that it has agreed to sell its Local Media Group ("LMG") to Gray Television, Inc. (NYSE: GTN) for $2.7 billion in cash and will focus exclusively on its... More
Vaxart (VXRT) Reports Q1 Loss of $0.14/sh
May 3, 2021 8:03 AM EDTVaxart (NASDAQ: VXRT) reported Q1 EPS of ($0.14), versus ($0.02) reported last year. Revenue for the quarter came in at $506 thousand, versus $2.9 million reported last year.
For earnings history and earnings-related data on Vaxart (VXRT) click here.
... More